Aficamten’s Impact on Cardiac Function and Structure in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM Trial
Highlight
- Aficamten improves diastolic function and alters left ventricular volumes in symptomatic nonobstructive hypertrophic cardiomyopathy (HCM).
- Significant reductions in left ventricular ejection fraction (LVEF) and improvements in echocardiographic diastolic parameters were observed by week 36 and sustained through up to 72 weeks.
- Therapeutic benefits of aficamten extend beyond LV outflow tract obstruction reduction, addressing intrinsic myocardial dysfunction.
- Early and dose-dependent beneficial effects on cardiac structure and function were evident even within two weeks of treatment titration.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.